IPCA Laboratories

IPCA Laboratories DSCR

The Debt Service Coverage Ratio (DSCR) of IPCA Laboratories (IPCALAB.NS) as of Nov 18, 2026 is 10.47. In the previous year, Debt Service Coverage Ratio (DSCR) was 1.21 — a change of 762.83% (higher).

DSCR

10.47

YoY

762.83%

Last updated:

Debt Service Coverage Ratio (DSCR) of IPCA Laboratories is 2026 10.47 . Debt Service Coverage Ratio (DSCR) of IPCA Laboratories was 2025 1.21 . It decreases by 762.83% higher compared to the previous year.

The IPCA Laboratories DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2019
1.43 INR
Jan 1, 2020
1.34 INR
Jan 1, 2021
5.62 INR
Jan 1, 2022
1.11 INR
Jan 1, 2023
0.61 INR
Jan 1, 2024
0.87 INR
Jan 1, 2025
1.21 INR
Jan 1, 2026
10.47 INR
The IPCA Laboratories DSCR history
YEARDSCRYoY
10.47+762.83%
1.21+40.11%
0.87+42.96%
0.61-45.21%
1.11-80.33%
5.62+320.65%
1.34-6.54%
1.43+98.20%
0.72+35.33%
0.53-49.69%
1.06+225.31%
0.33-44.11%
0.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Debt Service Coverage Ratio (DSCR) of IPCA Laboratories is 10.47 in 2026.

Debt Service Coverage Ratio (DSCR) of IPCA Laboratories changed from 1.21 to 10.47, representing a 762.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IPCA Laboratories

All Key Metrics — IPCA Laboratories